Theme A Session 6: HTLV-1 – is this important for Australia?
Tracks
.
| Wednesday, September 26, 2018 |
| 11:00 AM - 12:30 PM |
| Ionic (Ground Floor) |
Details
Understanding the nature of HTLV-1c virology, pathogenesis, clinical presentation, transmission, epidemiology and the concerns that this virus presents for Australian health.
Speaker
Lloyd Einsiedel
Head, Infection and Chronic Disease
Baker Institute
Clinical aspects of the pathogenesis and epidemiology of HTLV-1 in Central Australia
11:00 AM - 11:20 AMBiography
Professor Damian Purcell
Professor of Virology and Theme Leader for Viral Infectious Diseases
Uni Melbourne, Doherty Institute
Mr James Cooney
Phd Student
The Walter And Eliza Hall Institute
Tenofovir Alafenamide Reduces Transmission of Human T-Leukeamia Virus 1 (HTLV-1) in a Humanised Mouse Model of Infection
11:40 AM - 12:00 PMBiography
James Cooney is a PhD student in the Pellegrini Laboratory at the Walter and Eliza Hall Institute of Medical Research. His research examines the efficacy of therapeutic interventions for the treatment and prevention of HTLV-1 in a pre-clinical model of disease, with a strong clinical translation focus.
Mr Joel Liddle
Research Officer
Baker Institute
The Prevalence And Clinical Associations Of HTLV-1 Infection In A Remote Indigenous Community
12:00 PM - 12:15 PMBiography
Joel Liddle Perrurle is an Eastern/Central Arrernte man from Central Australia, currently employed as a Research Officer with the Baker Heart and Diabetes Institute in Alice Springs. Joel's primary role is researching HTLV-1 prevalence in Central Australia and involved with community engagement activities within the research.
Dr Caroline Bartolo
ID physician
Barwon Health
Chair
Shane Schinke
Project Manager
Baker Heart & Diabetes Institute (Alice Springs)
Stuart Turville
Kirby Institute
